Sandoz Group AG SANDOZ GROUP ORD .../ CH1243598427 /
5/24/2024 5:19:23 PM | Chg. - | Volume | Bid6:00:09 AM | Ask6:00:09 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
32.17CHF | - | 80,833 Turnover: 699,394.51 |
-Bid Size: - | -Ask Size: - | 16.89 bill.CHF | - | - |
GlobeNewswire
8/21
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sando...
GlobeNewswire
8/14
Stevie® Awards Announce Winners in The 21st Annual International Business Awards® from Across the Gl...
GlobeNewswire
8/12
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...
GlobeNewswire
8/7
Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
7/25
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory dise...
GlobeNewswire
7/1
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
GlobeNewswire
5/22
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
5/13
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/9
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
4/30
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of San...
GlobeNewswire
4/30
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire
4/22
Samsung Bioepis Gains European Commission Approval For PYZCHIVA™, a Biosimilar to Stelara (Ustekinum...
GlobeNewswire
4/22
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immun...
GlobeNewswire
3/21
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for l...